Price
$355.93
Increased by +1.67%
Dollar volume (20D)
133.26 M
ADR%
2.13
Earnings report date
Oct 30, 2024
Shares float
40.80 M
Shares short
4.08 M [10.01%]
Shares outstanding
44.49 M
Market cap
15.58 B
Beta
0.57
Price/earnings
16.10
20D range
337.52 362.52
50D range
310.00 366.08
200D range
208.62 366.08

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.

It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.

The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jul 31, 24 5.85
Increased by +11.64%
6.40
Decreased by -8.59%
May 1, 24 6.17
Increased by +26.95%
5.65
Increased by +9.20%
Feb 21, 24 4.36
Increased by +63.30%
4.19
Increased by +4.06%
Nov 1, 23 5.38
Increased by +9.57%
5.04
Increased by +6.75%
Aug 2, 23 5.24
Increased by +117.43%
4.51
Increased by +16.19%
May 3, 23 4.86
Decreased by -3.38%
4.52
Increased by +7.52%
Feb 22, 23 2.67
Increased by +13.62%
4.51
Decreased by -40.80%
Nov 2, 22 4.91
Increased by +43.57%
3.89
Increased by +26.22%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 714.90 M
Increased by +19.85%
278.10 M
Increased by +7.29%
Increased by +38.90%
Decreased by -10.48%
Mar 31, 24 677.70 M
Increased by +33.70%
306.60 M
Increased by +27.27%
Increased by +45.24%
Decreased by -4.80%
Dec 31, 23 614.70 M
Increased by +25.07%
217.10 M
Increased by +64.35%
Increased by +35.32%
Increased by +31.41%
Sep 30, 23 609.40 M
Increased by +18.10%
267.60 M
Increased by +11.83%
Increased by +43.91%
Decreased by -5.31%
Jun 30, 23 596.50 M
Increased by +27.76%
259.20 M
Increased by +123.45%
Increased by +43.45%
Increased by +74.90%
Mar 31, 23 506.90 M
Increased by +9.74%
240.90 M
Increased by +0.42%
Increased by +47.52%
Decreased by -8.50%
Dec 31, 22 491.50 M
Increased by +18.38%
132.10 M
Increased by +17.74%
Increased by +26.88%
Decreased by -0.54%
Sep 30, 22 516.00 M
Increased by +16.03%
239.30 M
Increased by +47.08%
Increased by +46.38%
Increased by +26.76%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY